[

covaxin

]
PAGE 13

Latest from covaxin

PM congratulates scientists at Bharat Biotech for progress in Covaxin trials

The phase 3 trial is being conducted across India on 26,000 participants.
PM Modi at the Bharat Biotech facility in Hyderabad.(@narendramodi/Twitter)
PM Modi at the Bharat Biotech facility in Hyderabad.(@narendramodi/Twitter)
Updated on Nov 28, 2020 06:43 PM IST
Copy Link
Hindustan Times, Hyderabad | By

No complaint from volunteers given Bharat Biotech’s Covaxin: Ahmedabad doctor

Dr Parul Bhatt, the medical superintendent of the Sola Civil Hospital in Gujarat’s Ahmedabad, said the second dose of Bharat Biotech International Limited’s Covid-19 vaccine will now be given after 28 days.
People wait during the administration of Covaxin, a government-backed experimental Covid-19 vaccine, during its human trials, at the Gujarat Medical Education & Research Society in Ahmedabad, on Thursday.(PTI Photo)
People wait during the administration of Covaxin, a government-backed experimental Covid-19 vaccine, during its human trials, at the Gujarat Medical Education & Research Society in Ahmedabad, on Thursday.(PTI Photo)
Updated on Nov 27, 2020 05:41 PM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Meenakshi Ray

Covid-19 vaccine update: COVAXIN trials in Gujarat, AstraZeneca admits ‘error’

China National Biotec Group Company has applied to Chinese health regulators to bring its candidate to the market. In Brazil, meanwhile, America’s Pfizer Inc has started the process to get its candidate registered.
FILE PHOTO: A woman holds a small bottle labeled with a
FILE PHOTO: A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo(REUTERS)
Updated on Nov 26, 2020 05:06 PM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Karan Manral

Covid-19 vaccine update: India to immunise 250 million citizens, US vaccinations might begin in December

The United Kingdom could give approval to Pfizer’s vaccine candidate this week, a report claimed. Meanwhile, the official Twitter account of Russia’s vaccine candidate Sputnik V claimed the price per dose of the vaccine would be “much lower” than that of Moderna and Pfizer’s vaccine candidates.
FILE PHOTO: Trailers are shown in a city parking lot after a Phase 3 trial location of Johnson & Johnson's Janssen (COVID-19) vaccine candidate was announced in National City during the outbreak of the coronavirus disease (COVID-19) in National City, California, U.S., October 13, 2020. REUTERS/Mike Blake(REUTERS)
FILE PHOTO: Trailers are shown in a city parking lot after a Phase 3 trial location of Johnson & Johnson's Janssen (COVID-19) vaccine candidate was announced in National City during the outbreak of the coronavirus disease (COVID-19) in National City, California, U.S., October 13, 2020. REUTERS/Mike Blake(REUTERS)
Updated on Nov 23, 2020 01:42 PM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Karan Manral

Covid-19 vaccine updates: Bharat Biotech to recruit volunteers for trial, Pfizer files for emergency use authorisation

Britain’s AstraZeneca has launched phase three trials of an antibody combination drug, called AZD7442, that it hopes could be used to protect those at risk of contracting the coronavirus disease for up to 12 months.
Vials with a sticker reading,
Vials with a sticker reading, "Covid-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Pfizer logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic
Updated on Nov 21, 2020 08:13 AM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Karan Manral

Haryana health minister Anil Vij takes trial shot of Bharat Biotech’s Covid-19 vaccine

Vij, who also holds the state home portfolio, had volunteered to be the first candidate for the trial shot of Covaxin. Bharat Biotech has started conducting phase 3 trials of the vaccine candidate.
Haryana health minister Anil Vij (ANI)
Haryana health minister Anil Vij (ANI)
Updated on Nov 20, 2020 06:48 PM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Karan Manral

Covid-19 vaccine update: Covaxin phase 3 trials to begin in Haryana today, minister to take shot

Adar Poonawalla, the chief executive of Serum Institute of India, said his company may sell Covishield, the Covid-19 vaccine being developed by Oxford University, for around Rs 500-600 per shot.
FILE PHOTO: Small bottles labeled with
FILE PHOTO: Small bottles labeled with "Vaccine" stickers stand near a medical syringe in front of displayed "Coronavirus Covid-19" words in this illustration taken April 10, 2020 (REUTERS/Dado Ruvic/Illustration/File Photo)
Updated on Nov 20, 2020 08:27 AM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Karan Manral

Haryana’s Health Minister Anil Vij to be administered trial dose of Covid-19 vaccine Covaxin

Vij, who is an MLA from Ambala Cantt, had on Wednesday said the third phase of trial of Covaxin will begin in the state on November 20 and had offered to be the first volunteer to get vaccinated.
Haryana health minister Anil Vij.(Keshav Singh/Hindustan Times)
Haryana health minister Anil Vij.(Keshav Singh/Hindustan Times)
Updated on Nov 19, 2020 11:53 PM IST
Copy Link
Chandigarh | ByPress Trust of India | Posted by Shankhyaneel Sarkar

Covid-19 vaccine update: Bharat Biotech begins phase 3 trials, Moderna says its candidate nearly 95% effective

Meanwhile, Johnson and Johnson has launched a second phase 3 trial, besides its existing one. Also, India is reportedly in talks with several firms over their respective coronavirus vaccine candidates with regards to the progress of trials, vaccine efficacy, safety etc.
FILE PHOTO: A man rides his motorcycle past a parked bus of Bharat Biotech outside its office in Hyderabad (REUTERS/Stringer/File Photo)
FILE PHOTO: A man rides his motorcycle past a parked bus of Bharat Biotech outside its office in Hyderabad (REUTERS/Stringer/File Photo)
Updated on Nov 17, 2020 08:57 AM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Karan Manral

Bharat Biotech starts Phase 3 trial for its anti Covid vaccine in India

The Phase III trials will involve 26,000 volunteers across India, conducted in partnership with ICMR.
Volunteers for the trial are adults above 18 years of age.(REUTERS Photo)
Volunteers for the trial are adults above 18 years of age.(REUTERS Photo)
Updated on Nov 16, 2020 08:18 PM IST
Copy Link
Hindustan Times, New Delhi | ByRhythma Kaul | Edited by Abhinav Sahay

Bharat Biotech’s Covid-19 vaccine ‘Covaxin’ into phase-3 trials

Covaxin is being developed by BharatBiotech, in collaboration with the ICMR - National Institute of Virology (NIV).
A man rides his motorcycle past a parked bus of Indian biotechnology company Bharat Biotech outside its office in Hyderabad.(REUTERS)
A man rides his motorcycle past a parked bus of Indian biotechnology company Bharat Biotech outside its office in Hyderabad.(REUTERS)
Updated on Nov 16, 2020 07:49 PM IST
Copy Link
Hyderabad | ByPress Trust of India | Posted by Arpan Rai

Covid-19 vaccine updates: Over 250 register for Covaxin trial, Sputnik-V to reach Kanpur trial

So far, as many as 53,945,763 people have been infected by the Covid-19 across the world, numbers published by the John Hopkins University show. Most of the fresh cases were reported from the United States and Europe.
A nurse prepares Russia's ‘Sputnik-V’ vaccine against the coronavirus disease (Covid-19) for inoculation at a clinic in Tver, Russia.(Reuters)
A nurse prepares Russia's ‘Sputnik-V’ vaccine against the coronavirus disease (Covid-19) for inoculation at a clinic in Tver, Russia.(Reuters)
Updated on Nov 15, 2020 03:44 PM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Shivani Kumar

Doctors, MBBS students among 30 crore people to get Covid-19 vaccine first, Aadhaar not mandatory

The beneficiaries will be tracked through Aadhaar, but it won’t be mandatory. In case a person doesn’t have an Aadhaar card, any government photo identity will be used.
A volunteer getting a vaccine shot in Pune’s Bharati Hospital and Research Centre. (Photo by Ravindra Joshi/HT PHOTO)
A volunteer getting a vaccine shot in Pune’s Bharati Hospital and Research Centre. (Photo by Ravindra Joshi/HT PHOTO)
Updated on Nov 07, 2020 11:31 AM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Poulomi Ghosh

Covid-19 vaccine update: Bharat Biotech candidate launch and AstraZeneca’s hopes

Hungary has said it will import small doses of Russian-made Sputnik V for late stage trials, by December. Meanwhile, Australia has agreed to buy 50 million more doses of two more vaccine candidates.
A woman holds a small bottle labeled with a
A woman holds a small bottle labeled with a "Coronavirus Covid-19 Vaccine" sticker and a medical syringe in this illustration taken, October 30, 2020 (REUTERS/Dado Ruvic/File Photo)
Updated on Nov 06, 2020 06:43 PM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Karan Manral

Bharat Biotech’s Covaxin could be launched in Feb: Govt scientist

A launch in February would make COVAXIN the first India-made vaccine to be rolled out.
Bharat Biotech’s Covaxin against coronavirus could be launched in February: Govt scientist
Bharat Biotech’s Covaxin against coronavirus could be launched in February: Govt scientist
Updated on Nov 05, 2020 04:23 PM IST
Copy Link
New Delhi | ByReuters

Bharat Biotech to launch Covaxin in Q2 2021

The company’s vaccine candidate -Covaxin- has been developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV) using inactivated Sars-Cov-2, the virus that causes Covid-19. The virus was isolated in an ICMR lab.
It said its immediate focus is to conduct the Phase 3 trials successfully across sites in the country.(AP)
It said its immediate focus is to conduct the Phase 3 trials successfully across sites in the country.(AP)
Published on Nov 01, 2020 11:27 AM IST
Copy Link
Hindustan Times, New Delhi | ByPress Trust of India| Posted by Susmita Pakrasi

News updates from Hindustan Times: AIIMS to submit proposal for phase 3 trials of Covaxin next week and all the latest news

Here are today’s top news, analysis, and opinion. Know all about the latest news and other news updates from Hindustan Times
A health worker collects swab samples for Covid- 19 tests.(PTI)
A health worker collects swab samples for Covid- 19 tests.(PTI)
Updated on Oct 31, 2020 08:55 AM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com

News updates from Hindustan Times:Punjab farm bills offer little on ground and all the latest news

Three out of four bills passed by the Congress-led Punjab government on October 20 to negate contentious central legislations on how farmers do business are unlikely to invalidate the laws already passed by Parliament(AP)
Three out of four bills passed by the Congress-led Punjab government on October 20 to negate contentious central legislations on how farmers do business are unlikely to invalidate the laws already passed by Parliament(AP)
Updated on Oct 24, 2020 09:18 AM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com

Bharat Biotech to submit revised Phase 3 clinical trial protocol to DCGI by next week

Covaxin is India’s first vaccine candidate against Covid-19
Human clinical trials for Covaxin began across India in July 2020. As per the current plan, the Phase 3 trial, to determine vaccine efficacy, will begin early to mid-November this year.(Representational Photo/AP)
Human clinical trials for Covaxin began across India in July 2020. As per the current plan, the Phase 3 trial, to determine vaccine efficacy, will begin early to mid-November this year.(Representational Photo/AP)
Updated on Oct 24, 2020 08:31 AM IST
Copy Link
Hindustan Times,New Delhi | By

Covid-19: Bharat Biotech in talks to take vaccine candidate global

The company, based in Hyderabad, this week received initial approval from Indian authorities to conduct late-stage trials for its vaccine candidate, COVAXIN.
India’s Zydus Cadila is currently conducting mid-stage trials of its own vaccine hopeful, while Serum Institute is making potential vaccines from AstraZeneca, Novavax and Codagenix Inc, as well as developing its own.(Reuters file photo. Representative image)
India’s Zydus Cadila is currently conducting mid-stage trials of its own vaccine hopeful, while Serum Institute is making potential vaccines from AstraZeneca, Novavax and Codagenix Inc, as well as developing its own.(Reuters file photo. Representative image)
Updated on Oct 23, 2020 08:41 PM IST
Copy Link
Bengaluru | ByReuters| Posted by: Harshit Sabarwal

Covaxin: Bharat Biotech gets nod from DCGI panel for Phase III trials

The nod is subject to amendment in how primary efficacy endpoint for symptomatic cases be studied in Phase 3 trials, the panel further stated.
The panel added that the recommendation is after assessing data from Phase I & II as well as animal challenge study.(HT file photo)
The panel added that the recommendation is after assessing data from Phase I & II as well as animal challenge study.(HT file photo)
Updated on Oct 23, 2020 08:32 AM IST
Copy Link
Livemint, New Delhi | ByMint Correspondent

From Moderna’s trial results to Covaxin’s immunity booster: Covid-19 vaccine latest developments

India’s Covid-19 case count rose to 67.57 lakh with 72,049 new cases in a day, while 57,44,693 people have recovered so far pushing the national recovery rate to 85.02%, according to the Union Health Ministry data on Wednesday.
The Covid-19 case mortality rate has further declined to 1.55%.(AP)
The Covid-19 case mortality rate has further declined to 1.55%.(AP)
Updated on Oct 07, 2020 06:26 PM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com| Edited by Susmita Pakrasi

UP: BRD Medical College to start Covaxin phase-3 trial in mid-October

Phase three of drug trials involve efficacy and monitoring of adverse reactions. The college has constituted a three-member doctors’ team to prepare the standard operating procedure for the trials
The earlier two phases of the trials were held at two private medical hospitals in Gorakhpur and Kanpur.(Representational Image)
The earlier two phases of the trials were held at two private medical hospitals in Gorakhpur and Kanpur.(Representational Image)
Updated on Sep 29, 2020 09:38 AM IST
Copy Link
Hindustan Times, Lucknow | By

Rohtak’s PGIMS begins second phase of clinical trials for indigenous Covid vaccine, Covaxin

12 volunteers administered dose of vaccine through intramuscular injection, next dose after 28 days
Covaxin, which has been developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), will be tested on 50 volunteers at Post Graduate Institute of Medical Sciences, Rohtak, in Phase 2.(Reuters file photo)
Covaxin, which has been developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), will be tested on 50 volunteers at Post Graduate Institute of Medical Sciences, Rohtak, in Phase 2.(Reuters file photo)
Published on Sep 10, 2020 02:14 AM IST
Copy Link
Hindustan Times, Rohtak | ByHT Correspondent

‘If it holds in future tests too’: UP doctor on promising Covaxin results

No one complained of any side effects then, nor did they in three weeks after they were administered the vaccine, said experts.
The vaccine, known as Covaxin, has been developed by Bharat Biotech. (Photo by Ravindra Joshi/HT PHOTO)
The vaccine, known as Covaxin, has been developed by Bharat Biotech. (Photo by Ravindra Joshi/HT PHOTO)
Updated on Aug 25, 2020 12:13 AM IST
Copy Link
Hindustan Times, Kanpur | ByHaidar Naqvi

Covaxin gets nod for skin trial: Latest on India’s Covid-19 vaccine candidate

Human trials of Covaxin started about two week ago and it may be available by the end of the year, Union minister of health and family welfare Harsh Vardhan has said.
Covaxin trials are being conducted on 1,125 patients at 12 hospitals across the country
Covaxin trials are being conducted on 1,125 patients at 12 hospitals across the country
Updated on Aug 23, 2020 09:19 AM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Kanishka Sarkar

Want to enrol in a vaccine trial? Know your eligibility

There are currently three Covid-19 vaccines at various stages of development in India. Prime Minister Narendra Modi said on August 15 that along with a plan for mass production, the road map for distribution of vaccines to every Indian was in place.
A healthcare worker wearing personal protective equipment (PPE) takes a swab from a migrant worker, who returned to Delhi from his native state, for a rapid antigen test at a bus terminal, amidst the coronavirus disease (Covid-19) outbreak in New Delhi.(REUTERS)
A healthcare worker wearing personal protective equipment (PPE) takes a swab from a migrant worker, who returned to Delhi from his native state, for a rapid antigen test at a bus terminal, amidst the coronavirus disease (Covid-19) outbreak in New Delhi.(REUTERS)
Updated on Aug 23, 2020 05:31 AM IST
Copy Link
Hindustan Times, New Delhi | By

Bharat Biotech gets nod to conduct Covaxin trial through skin

Currently, the vaccine was being tested through intramuscular route, where it is injected directly into the muscle. The trial is being run on 1,125 patients at 12 hospitals across the country including All India Institute of Medical Sciences.
The CDSCO is a pharmaceutical regulatory body under the health ministry. It regulates the quality of drugs and vaccines in the country.(Reuters file photo for representation)
The CDSCO is a pharmaceutical regulatory body under the health ministry. It regulates the quality of drugs and vaccines in the country.(Reuters file photo for representation)
Updated on Aug 22, 2020 10:00 PM IST
Copy Link
Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Shivani Kumar

Three volunteers get second dose of Covaxin at PGIMS

Three volunteers were administered the second dose of Covaxin at the Post Graduate Institute of Medical Sciences (PGIMS) on Friday. Dr Savita Verma, principal investigator of the human trials at the Rohtak facility, said these three volunteers had completed the 14-day period after receiving the first dose of 0.
HT Image
HT Image
Updated on Aug 01, 2020 01:28 AM IST
Copy Link
BySunil Rahar, Rohtak

Scientists analysing results of phase one safety trial of Covaxin

The institute is among 12 other sites the ICMR has approved for the human trial of the vaccine.
The institute is among 12 other sites the ICMR has approved for the human trial of the vaccine.(Satish Bate/HT Photo)
The institute is among 12 other sites the ICMR has approved for the human trial of the vaccine.(Satish Bate/HT Photo)
Updated on Jul 31, 2020 11:16 PM IST
Copy Link
Hindustan Times, Patna | By
SHARE
  • 13
  • 14
  • ...
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Friday, January 28, 2022